[A17-26] Rolapitant (prevention of nausea and vomiting in chemotherapy) - Benefit assessment according to §35a Social Code Book V
Last updated 01.09.2017
Project no.:
A17-26
Commission:
Commission awarded on 01.06.2017 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Cancer
Indication:
Prevention of nausea and vomiting in chemotherapy
Result of dossier assessment:
Added benefit not proven due to a lack of suitable data
Note:
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
Federal Joint Committee (G-BA)
2017-11-17 A G-BA decision was published.